inhibitor (Deutetrabenazine) is proved to be effective in the cure of involuntary movements in patients with tardive dyskinesia, and the SLC18A2 blocker (Tetrabenazine) is the only US Food and Drug Administration-approved drug for Huntington’s disease (Hu et al., 2020). This evidence concerns the gene SLC18A2 and Huntington disease.